A1 Refereed original research article in a scientific journal

Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia




AuthorsJenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, Deep-Soboslay A, Innis RB, Kleinman JE

PublisherELSEVIER SCIENCE BV

Publication year2012

JournalSchizophrenia Research

Journal name in sourceSCHIZOPHRENIA RESEARCH

Journal acronymSCHIZOPHR RES

Volume141

Issue2-3

First page 185

Last page188

Number of pages4

ISSN0920-9964

DOIhttps://doi.org/10.1016/j.schres.2012.07.021(external)


Abstract
This study sought to determine whether cannabinoid-1 (CB1) receptor binding was altered in the postmortem dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (schizophrenia; n = 47) compared to controls (n = 43). The CB1 receptor inverse agonist radioligand [H-3]MePPEP was used to measure specific binding to CB1 receptors. The specific binding of [H-3]MePPEP to CB1 receptors was 20% higher in patients with schizophrenia than in controls. Power analyses suggested that 53 subjects per group would be needed to detect a similar difference in vivo with positron emission tomography (PET) and the structurally related inverse agonist radioligand [F-18]FMPEP-d(2) (80% statistical power, p<0.05). Published by Elsevier B.V.



Last updated on 2024-26-11 at 17:47